This is the authors' abstract. We don't add key points for this paper.
Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody approved for the treatment of advanced and metastatic renal cell carcinoma. Treatment with nivolumab is characterised by favourable toxicity profile. The occurrence of grade 3 and 4 toxicity during the therapy is low. This article describes a medical history of a patient with metastatic renal cell carcinoma treated with nivolumab.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tomczak et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: